Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Long-Term Debt Repayments (2021 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $248911.0 as the latest value for Q1 2022.

  • On a quarterly basis, Long-Term Debt Repayments fell 39.24% to $248911.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $248911.0, a 485.2% increase, with the full-year FY2022 number at $248911.0, up 485.2% from a year prior.
  • Long-Term Debt Repayments was $248911.0 for Q1 2022 at Inhibikase Therapeutics, up from -$367128.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $409662.0 in Q1 2021 to a low of -$367128.0 in Q2 2021.